Team 5 – Mononuclear Phagocytes in Cardiometabolic Diseases

Team headed by Philippe Lesnik

Team 5 is focused on the study of mononuclear phagocytes in the context of cardiometabolic diseases. The team main objective is to better understand how different mononuclear phagocytes subsets impact on chronic metabolic disorders, with particular emphasis on macrophages and dendritic cells. To this aim, unique mouse models and preclinical approaches are used to decipher the complex interactions between mononuclear phagocytes subsets and metabolic tissues. In addition, this team builds on recent cutting-edge preclinical and clinical proof-of-concepts evidencing a relationship between intestinal microbiota, immune cells and cholesterol metabolism in the host.

This team is attached to the doctoral school 394 “Physiologie, Physiopathologie et Thérapeutique”.

Principal investigators’ groups:

In team 5, Emmanuel Gautier‘s group works on the diversity and functionality of mononuclear cell subsets in cardiometabolic diseases. His group is interested in delineating the role of mononuclear phagocytes (monocytes, macrophages and dendritic cells) in chronic inflammatory conditions such as cardiometabolic diseases (atherosclerosis, obesity, NASH). More specifically, we study how dendritic cell subsets, tissue resident and monocyte-derived macrophages impact on cardiometabolic diseases development, and developed tools to target these subsets in vivo. Our studies are based on integrated approaches combining molecular, cellular biology and animal models. Particular attention is given to the interactions between inflammatory stimuli, mononuclear phagocytes, lipid and carbohydrate metabolisms as well as the gut microbiota.

Dr. Thierry Huby’s main research focuses on understanding the role of tissue resident and monocyte-derived macrophages in cholesterol metabolism given particular attention to specific cellular players, such as the scavenger receptor SCARB1, but also, specific tissue macrophage populations such as Kupffer cells. Our experimental approaches mainly involve use of mouse models to target candidate genes and cell types to evaluate their contribution in vivo in maintaining cholesterol homeostasis in the context of cardio-metabolic diseases.
aaa